1. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
- Author
-
Robert D. Morgan, George J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. Clamp, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Emma R. Woodward, Fiona Lalloo, Emma J. Crosbie, Richard J. Edmondson, Andrew J. Wallace, Gordon C. Jayson, and D. Gareth R. Evans
- Subjects
BRCA2 Protein ,Ovarian Neoplasms ,Cancer Research ,Germ Cells ,Oncology ,BRCA1 Protein ,Humans ,Female ,Genetic Testing ,Carcinoma, Ovarian Epithelial ,Germ-Line Mutation ,Article ,Aged - Abstract
National guidelines recommend testing all cases of non-mucinous epithelial ovarian cancer (NMEOC) for germline (blood) and somatic (tumour) BRCA1/2 pathogenic variants (PVs). We performed paired germline and somatic BRCA1/2 testing in consecutive cases of NMEOC (n = 388) to validate guidelines. Thirty-four somatic BRCA1/2 (sBRCA) PVs (9.7%) were detected in 350 cases with germline BRCA1/2 (gBRCA) wild-type. All sBRCA PVs were detected in non-familial cases. By analysing our regional germline BRCA1/2 database there were 92/1114 (8.3%) gBRCA PVs detected in non-familial cases (only 3% ≥70 years old) and 245/641 (38.2%) in familial cases. Germline non-familial cases were dominated by BRCA2 in older women (8/271 ≥ 70 years old, all BRCA2). The ratio of sBRCA-to-gBRCA was ≤1.0 in women aged
- Published
- 2022